key: cord-0277187-cxnytj4m
authors: Algarni, A. M.; Alfaifi, M. S.; Al Bshabshe, A. A.; Omair, O. M.; Alsultan, M. A.; Alzahrani, H. M.; Alali, H. E.; Alsabaani, A. A.; Alqarni, A. M.; Alghanem, S. A.; Basulaib, N. M.; Al Mufareh, B. S.; Al Gamdi, B. A.; Al-Kashmiri, A. M.; Almemari, A. M.; Sindi, A. A.; Ozturan, I. U.; Alhadhira, A. A.; Shujaa, A. S.; Alotaibi, A. H.; Awladthani, M. M.; Alghamdi, M. M.; Almarshed, A. A.; AlQahtani, A. M.; Harris, T. R.; Alyahya, B. A.; AlAsiri, S. A.; Abuzeyad, F. H.; Kazim, S. N.; Al-Fares, A. A.; Alshahrani, N. H.; Almazroua, F. Y.; Al Hinai, N. N.; Alhamadi, B. N.; Al jumaan, M. A.; Marzook,
title: Prognostic accuracy of qSOFA score, SIRS criteria, and EWSs for in-hospital mortality among adult patients presenting with suspected infection to the emergency department (PASSEM): protocol for an international multicentre prospective external validation cohort study
date: 2022-03-22
journal: nan
DOI: 10.1101/2022.03.19.22272537
sha: a230832d5a5f9e2370517b5f061432a857285318
doc_id: 277187
cord_uid: cxnytj4m

Introduction Early identification of a patient with infection who may develop sepsis is of utmost importance. Unfortunately, this remains elusive because no single clinical measure or test can reflect complex pathophysiological changes in patients with sepsis. However, multiple clinical and laboratory parameters indicate impending sepsis and organ dysfunction. Screening tools using these parameters can help identify the condition, such as SIRS, quick SOFA (qSOFA), National Early Warning Score (NEWS), or Modified Early Warning Score (MEWS). We aim to externally validate qSOFA, SIRS, and NEWS/NEWS2/MEWS for in-hospital mortality among adult patients with suspected infection who presenting to the emergency department. Methods and analysis PASSEM study is an international prospective external validation cohort study. For 9 months, each participating centre will recruit consecutive adult patients who visited the emergency departments with suspected infection and are planned for hospitalisation. We will collect patients' demographics, vital signs measured in the triage, initial white blood cell count, and variables required to calculate Charlson Comorbidities Index; and follow patients for 90 days since their inclusion in the study. The primary outcome will be 30-days in-hospital mortality. The secondary outcome will be intensive care unit (ICU) admission, prolonged stay in the ICU (i.e., >72 hours), and 30- as well as 90-days all-cause mortality. The study started in December 2021 and planned to enrol 2851 patients to reach 200 in-hospital death. The sample size is adaptive and will be adjusted based on prespecified consecutive interim analyses. Ethics and dissemination The Aseer Regional Committee for Research Ethics in the General Directorate of Health Affairs-Aseer Region has approved this study. Informed consent is not required for this study due to its complete observational nature and absence of interventions or invasive procedures. We will publish study's results in peer-reviewed journals and may present them at scientific conferences.

Over the past decade, there has been continued focus on sepsis as a prevalent condition that accounts for 10% of admissions to intensive care units (ICUs) and is associated with a 10-20% in-hospital mortality rate. 1-5 Standardised protocols and physician awareness have signi cantly improved survival, but mortality rates remain high between 20% and 36%, with ~270,000 deaths annually in the United States. [6] [7] [8] It has been estimated that 80% of sepsis cases are identi ed and treated in the emergency department (ED), and the remainder develop sepsis during hospitalisation with other conditions. 7

In 2016, the Society of Critical Care Medicine/European Society of Intensive Care Medicine (SCCM/ESICM) task force rede ned sepsis based on organ dysfunction and mortality prediction. 9-11 Sepsis now is de ned as lifethreatening organ dysfunction caused by dysregulated host response to infection. is de nition emphasises the complexity of the disease that cannot be explained by infection or body response alone. Acute change in Sequential Organ Failure Assessment (SOFA) score ≥2 indicates sepsis-related organ dysfunction and is associated with inhospital mortality. Systemic In ammatory Response Syndrome (SIRS) and "severe sepsis" terms were omitted from the most recent de nition. SIRS has been criticised for its poor speci city, while "severe sepsis" may underestimate sepsis's seriousness. A subset of patients may develop septic shock with underlying profound organ dysfunction and excess mortality. Clinically, septic shock is de ned as persistent hypotension requiring vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mm Hg and serum lactate level ≥ 2 mmol/L (18 mg/dL) despite adequate volume resuscitation.

Early identi cation of a patient with infection who may develop sepsis is of utmost importance. 12 Unfortunately, this remains elusive because no single clinical measure or test can re ect the complex pathophysiological changes in patients with sepsis. However, multiple clinical and laboratory parameters indicate impending sepsis and organ dysfunction. Screening tools using these parameters can help identify the condition, such as SIRS, quick SOFA (qSOFA), National Early Warning Score (NEWS), or Modi ed Early Warning Score (MEWS) ( Table 1 and 2). 13 e 2016 SCCM/ESICM task force recommended using qSOFA, 11 while the 2021 Surviving Sepsis Campaign strongly recommended against its use compared with SIRS, NEWS, or MEWS as a single screening tool for sepsis or septic shock. 14 We hypothesised that qSOFA has greater prognostic accuracy than SIRS and EWSs (NEWS/NEWS2/MEWS). We developed a protocol for a prognostic study to determine whether qSOFA has a higher predictive performance for relevant clinical outcomes in adult patients with infection presenting to the ED.

Multiple studies have assessed qSOFA, SIRS, and EWSs validity in ED and showed con icting results. [15] [16] [17] [18] [19] [20] [21] One . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 22, 2022 13 None of the eligible studies included NEWS2; and the authors of the review could not perform a meta-analysis due to marked heterogeneity in patient selection, outcomes, and settings.

Moreover, studies have calculated the scores at di erent times. NEWS appeared more sensitive than qSOFA for predicting ICU admission and mortality at the commonly used thresholds (i.e., ≥2 for SIRS and qSOFA; ≥5 for NEWS, NEWS2, and MEWS), whereas qSOFA was more speci c. 13 is correlates with previous criticisms of qSOFA, which have low sensitivity for early risk assessment. [18] [19] [20] [21] We are unaware of any prospective studies that validate or speci cally studied the predictive accuracy of qSOFA score, SIRS criteria, or EWSs in the ED in Middle East region in general and Arab countries in particular. Moreover, previous international studies have limitations that a ect their validity. 13 Aim e purpose of this study is to externally validate qSOFA score, SIRS criteria, and EWSs for in-hospital mortality among adult patients with suspected infection presenting to the ED in the Middle East region. In an ED setting, it is crucial to take a patient's vital signs as early as possible to make decisions and predict the patient's outcome.

Hence, PASSEM study will use initial physiologic parameters the patient presented with, to the ED (triage vital signs) to calculate qSOFA, SIRS criteria, and EWSs, which might be more appropriate and pragmatic. e primary endpoint is in-hospital mortality within 30 days. e secondary endpoints are ICU admission, ICU length of stay, and all-cause mortality within 30-and 90-days following presentation to the ED.

is protocol describes a multicentre, prospective observational cohort study evaluating the prognostic accuracy of qSOFA score, SIRS criteria, and EWSs (NEWS/NEWS2/MEWS) for in-hospital mortality among adult patients presenting to the ED with suspected infection (NCT05172479). e study's outlines are shown in Figure 1 . e study duration is 12 months per centre (9 months for recruitment and 3 months for follow-up). Recruiting centres and recruitment status are shown in Table 3 (19 March 2022) .

A presumptive diagnosis of infection will be judged based on the opinion of the ED physician upon the initial patient presentation. If required, two experts from each recruiting centre will ascertain the diagnosis of infection on the 30 th day since inclusion to the study. Evidence of infection will be sought by analysing the patient's clinical, microbiological, and radiological data. Evidence of infection would be determined by either positive culture, other microbiological techniques (e.g., serological, or molecular), or radiological ndings. If all of these evidence measures were equivocal, clinical context will be used to con rm the presence of infection. In cases of disagreement, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 22, 2022. ;  https://doi.org/10.1101/2022.03.19.22272537 doi: medRxiv preprint consensus will be sought between the two experts. In all cases, the diagnosis of infection will be blinded to the output of the prediction models and the outcomes of patients.

PSSEM study will enrol all consecutive adult patients (age ≥18 years) presenting to the ED with suspected infection who are planned for hospitalisation (Box 1).

We will exclude patients who present to the ED due to non-infectious causes (e.g., autoimmune diseases, myocardial infarction, trauma, …etc.), pregnant woman, those who are transferred from other hospitals, or with "Do-Not-Resuscitate" (DNR) code status. Patients whose initial diagnosis of infection in the ED was not con rmed after the recruitment and follow-up will also be excluded (Box 1).

u Adult patient (ages ≥18 years).

u Suspected infection (based on the opinion of the emergency physician).

u Planned for hospitalisation.

u Willing to give oral informed consent (per centre policy).

u Presentation to ED is not due to infection (e.g., autoimmune diseases, myocardial infarction, stroke, venous thromboembolism, trauma, intoxication … etc.).

u Pregnancy.

u Transferred from another hospitals.

u Code status is "Do-Not-Resuscitate" (DNR).

u Elective admission to the hospital (i.e., not through emergency department).

u Initial diagnosis of infection in the ED was not confirmed a"er finishing of the recruitment and followup phase.

e key characteristics of PASSEM Study and the original derivation cohorts of qSOFA, SIRS, and EWSs that will be assessed are shown in Table 4 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 5 . Patients will undergo 4 phases: screening (Time-1 [T-1], 1-2 days), enrolment (T0), and in-hospital (T1, maximum 30 days after T0), and out-hospital follow-up (T2, maximum 90 days after T0).

A sta member will screen patients for eligibility and check their measured vital signs once they arrive at the ED (triage) and the investigator will enrol potentially eligible patients (i.e., age ≥18 years, with suspected infection, and planned for hospitalisation). First, a web-based electronic data capture system (EDC) will assign each patient to a participant number in ascending order. en, the investigator will collect and enter the patient's initial data (demographics, contact information, Charlson Comorbidity Index (CCI) components, and variables required for qSOFA, SIRS, and EWS scores calculation) in an electronic case report form (eCRF) (see online supplementary materials). If the patient is not eligible, we will close the patient record in the EDC and clarify the cause of exclusion.

Once enrolment is completed, the in-hospital follow-up phase will start (T1, maximum 30 days after T0) ( Table 5) .

Study team will monitor hospitalised patients' status (i.e., death, alive and either discharged, transferred to another hospital, or still hospitalised) by consulting their speci c medical registration number (MRN) in the recruiting centre.

is phase starts if the patient is discharged from the hospital or 30-days have passed since inclusion to the study (whenever earlier; T2, maximum 90 days after T0) ( Table 5 ). We will determine their status via telephone contact.

We will also evaluate hospitalised patients' situations by consulting their MRN in the recruiting centre. We will consider a patient lost to follow-up if we cannot reach them via telephone contact by the end of this phase.

e primary outcome of this study is 30-days in-hospital mortality. Secondary outcomes include ICU admission (within 30-days), ICU length of stay, and all-cause mortality within 30 and 90 days.

Lead investigator in each centre will extract the demographics, components of CCI, vital signs, and blood investigations from the medical record of each potentially eligible patient. Study team will use the patient's initial vital signs, level of consciousness (i.e., rst measurement in triage), WBC count, and partial pressure of carbon dioxide (pCO2) to calculate qSOFA, SIRS, and EWSs. Blood pressure will be measured by using an electronic sphygmomanometer and results will be recorded in millimetres of mercury (mmHg). MAP will be calculated from SBP and diastolic blood pressure (DBP) using the following equation:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 22, 2022 Pulse rate (recorded as beats/min) and oxygen saturation (recorded as a percentage) will be measured using an electronic pulse oximetry device. We will report whether the oxygen saturation reading was in room air or while a patient is on oxygen therapy. Body temperature will be measured orally or (axillary if necessary) by electronic thermometer and recorded as degree Celsius. A new-onset Glasgow Coma Scale (GCS) score of <15 will be considered signi cant for qSOFA calculation. If it is unclear whether a patient's confusion is 'new' or their usual state, we will assume the altered mental state/confusion is new until con rmed otherwise for all scores calculation.

Initial WBCs count (recorded in x10 9 /μL) and pCO2 (recorded in mmHg) will be obtained from the patient's medical record and entered into the eCRF.

In the PASSEM study, we chose the method suggested by Collins et al. 22 In this method, sample size calculation is data, a sample size of 2851 should be included. We will conduct an interim analysis after recruitment of 25%, 50%, and 75% of the target sample size to re-evaluate our assumptions and correct the sample size accordingly.

Continuous data will be reported as mean (SD) or median (IQR) and compared using unpaired t tests or analysis of variance and Mann-Whitney or Kruskal-Wallis test. Categorical variables variables will be expressed as number (percentage) and compared using a χ 2 test or a Fisher exact test. We will begin by calculating an overall area under the receiver operating characteristic curve (AUC of ROC curve) and generate calibration curves of the qSOFA, SIRS, and EWSs to predict the primary and secondary outcomes. Subsequent to assessing the model's overall performance; sensitivity, speci city, positive and negative predictive values will be calculated with cross tables for predicting primary and secondary outcomes for a qSOFA score of ≥2, SIRS of ≥2, and EWSs of ≥5. We will use the Kaplan-Meier method to estimate in-hospital and 90-day all-cause mortality. A log-rank regressions will be used to assess groups' di erences. Odd ratios (ORs) for in-hospital death, ICU admission, and 90-days all-cause mortality of qSOFA, SIRS, and EWSs will be estimated with a logistic regression analysis after adjustment for the patients' demographics, comorbidities, and CCI. e model t will be assessed by the calculation of the log-likelihood, Akaike information criterion (AIC), AUC, Bayesian information criterion (BIC), and D-statistics. To compare the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 22, 2022. ;  https://doi.org/10.1101/2022.03.19.22272537 doi: medRxiv preprint performance of qSOFA, SIRS and EWSs, we will use absolute net-reclassi cation index (NRI). e absolute NRI mathematically represents a net proportion of patients correctly reclassi ed by one model as compared to another. 24 Net reclassi cation involves classifying patients in risk categories and determining how a new model reclassi es patients into various risk categories compared with a previous model. Risk di erences are classi ed based on the actual outcome patients experienced (those who died vs those who did not).

A priori subgroup analyses will be conducted based on status of the following: COVID-19 (present vs absent), febrile neutropenia (present vs absent), solid organs or hematological cancers (present vs absent), autoimmune diseases (present vs absent), and severe comorbidities (CCI ≥3 vs <3), and race of the patient (Asian vs Black vs South Asian vs White) as permitted by sample size. If missing data is minimal (<5%) we will conduct a complete case analysis, otherwise we will use multiple imputation.

For all analyses, a 2-tailed P <0.05 will be considered statistically signi cant. Statistical analyses will be performed with STATA (StataCorp LLC).

We will use an encrypted, web-based EDC (Castor ® ) for this study. 25 Lead investigators (or their delegates) will enter clinical data on an eCRF at each participating centre. ey will make all entries, corrections, and alterations. e data manager of this study will provide all tools, instructions, and training necessary to complete the eCRF, and each user will be issued a unique username and password. e monitors will review the eCRFs, evaluate them for completeness and consistency, and compare them with the source documents to ensure no discrepancies. e Monitors cannot enter data in the eCRFs. Lead investigators must verify that all data entries in the eCRF are accurate and correct. If some assessments are not done, or speci c information is unavailable, not applicable, or unknown, they must indicate this in the eCRF. Finally, lead investigators must electronically sign o all patients' eCRF enrolled from their hospitals.

Data manager will lock the nal validated database so that no more change will be possible on the frozen data.

Subsequently, the principal investigator will receive the patient data (eCRF data + audit trail) for archiving at the investigational site and transference in a secure way to the biostatistical team in STATA format.

We will not involve patients or the public in the design, conduction, reporting, or dissemination of this study.

Informed consent is not required of this study due to its complete observational nature and absence of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) interventions or invasive procedures. e study does not impose any change in the standard practice of sepsis at the site. e bene t/risk ratio of participation in the study is excellent. Moreover, we expect that PASSEM Study results may improve patient care in the recruiting centre by allowing a better understanding of ideal tools to identify patients with sepsis.

is protocol complies with the principles laid down by the 59th World Medical Assembly and all applicable amendments laid down by the World Medical Assemblies, the applicable regulations per site, and any other relevant local requirement and laws. e Aseer Regional Committee for Research Ethics in the General Directorate of Health A airs-Aseer Region has approved this study. e principal investigator will also work closely with the lead investigators of other hospitals to obtain all necessary ethical approval from the Local IRBs (LIRBs) as requested by the policies of these hospitals.

Data manager of PASSEM study will not grant access to the EDC system or start the study until the principal investigator receives a copy of a written and dated approval/favourable signed opinion from each participating centre LIRB.

We will present any change in this protocol as an amendment in written form to the protocol. e principal investigator and lead investigators will sign the protocol amendment and then submitted to the LIRBs. Following approval, we will send the amendment to all participating investigators. e amendment cannot be acted upon before the outcome of this decision. However, the study team will submit minor modi cations (administrative modi cations, including a new recruitment centre) to the LIRBs for information purposes only.

We will publish study's results in peer-reviewed journals and may present them at scienti c conferences. We will follow recommendations of Transparent Reporting of a Multivariable Prediction Model For Individual Prognosis or Diagnosis (TRIPOD) guidelines. 26 e most signi cant results will be shared to the public through social networks.

In order to maintain con dentiality, we will not collect any patient's-identifying data (e.g., name, identi cation number, medical record number [MRN], etc.) in the eCRF. Instead, lead investigators will store such data in a separate list sheet speci ed for each participating centre. e lead investigator of each centre will maintain this list in strict con dence. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 22, 2022 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 22, 2022. ; Table 5 Study components

In hospital F/U Out hospital F/U

Severe sepsis and septic shock

Sepsis: a roadmap for future research

Trial of early, goal-directed resuscitation for septic shock

Goal-directed resuscitation for patients with early septic shock

A randomized trial of protocol-based care for early septic shock

Sepsis and septic shock: Pathogenesis and treatment perspectives

Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data

Does Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock? The Journal of emergency medicine

Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Sepsis: Diagnosis and Management

Comparison of qSOFA and Hospital Early Warning Scores for prognosis in suspected sepsis in emergency department patients: a systematic review

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department

Comparison of QSOFA score and SIRS criteria as screening mechanisms for emergency department sepsis. The American journal of emergency medicine

Low Accuracy of Positive qSOFA Criteria for Predicting 28-Day Mortality in Critically Ill Septic Patients During the Early Period A"er Emergency Department Presentation

Quick Sepsis-related Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for Detecting Clinical Deterioration in Infected Patients outside the Intensive Care Unit

SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis

Clinical Scores and Formal Triage for Screening of Sepsis and Adverse Outcomes on Arrival in an Emergency Department All-Comer Cohort

Comparison of SIRS, qSOFA, and NEWS for the early identification of sepsis in the Emergency Department

Sample size considerations for the external validation of a multivariable prognostic model: a resampling study

Minimum sample size for external validation of a clinical prediction model with a continuous outcome

Discrimination and calibration of clinical prediction models: Users' guides to the medical literature

Castor Electronic Data Capture Netherlands2021

Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement

*-Level of consciousness and new confusion ('C'), thus AVPU becomes ACVPU, where C represents new confusion. †-NEWS2 has a dedicated section (SpO2 Scale 2) for use in patients with hypercapnic respiratory failure who have clinically recommended oxygen saturation of 88-92%.